Synapse - Helena Yu

Results (285)

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors

Journal Article

Murciano-Goroff, Y. R.; Foglizzo, V.; Chang, J.; Rekhtman, N.; Sisk, A. E.; Gibson, J.; Judka, L.; Clemens, K.; Roa, P.; Ahmed, S. S.; more...
Clinical and Translational Medicine (2025)

Fulltext@MSK | Save

Management of EGFR-variant and ALK-positive non-small cell lung cancer brain metastasis

Editorial

Pike, L. R. G.; Yu, H.; Rusthoven, C. G.
JAMA Oncology (2025)

Fulltext@MSK | Save

ORCHARD: Osimertinib plus necitumumab in patients with epidermal growth factor receptor–mutated advanced non–small cell lung cancer with a secondary epidermal growth factor receptor alteration whose disease had progressed on first-line osimertinib

Journal Article

Riess, J. W.; de Langen, A. J.; Ponce, S.; Goldberg, S. B.; Piotrowska, Z.; Goldman, J. W.; Le, X.; Cho, B. C.; Yoneshima, Y.; Ambrose, H.; more...
JCO Precision Oncology (2025)

Fulltext@MSK | Save

Lung cancer and cardiovascular disease: Common pathophysiology and treatment-emergent toxicity

Review

El-Rayes, M.; Nardi Agmon, I.; Yu, C.; Osataphan, N.; Yu, H. A.; Hope, A.; Sacher, A.; Yu, A. F.; Abdel-Qadir, H.; Thavendiranathan, P.
JACC: CardioOncology (2025)

Fulltext@MSK | Save

Outcomes after radiation for oligoprogressive disease sites in patients with EGFR-mutant lung cancer treated with osimertinib

Journal Article

Chen, M. F.; Jeng, M. Y.; Ma, J.; Agrawal, P.; Dunne, E.; Boe, L. A.; Kris, M. G.; Huang, J.; Veeraraghavan, H.; Gomez, D.; more...
JCO Precision Oncology (2025)

Fulltext@MSK | Save

Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD

Meeting Abstract

Le, X.; Hendriks, L.; Morabito, A.; Bonanno, L.; Okamoto, I.; Goldman, J. W.; Yu, H. A.; Brustugun, O. T.; Halvorsen, T. O.; Kim, Y. J.; more...
Journal of Thoracic Oncology (2025)

Fulltext@MSK | Save

Phase I study of patritumab deruxtecan (HER3-DXd) in patients (pts) with advanced KRAS G12C non-small cell lung cancer (NSCLC): Study U102 cohort 5

Meeting Abstract

Paz-Ares, L.; Steuer, C.; Ruiter, G.; Nishio, M.; Murakami, H.; Kim, D. W.; Felip, E.; Baik, C. S.; Lin, C. C.; Massarelli, E.; more...
Journal of Thoracic Oncology (2025)

Fulltext@MSK | Save

TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib